Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease

Exclusion Criteria

• •Patient participated in investigational clinical trials in the last month prior to screening
• •Pregnant or breast-feeding woman or woman without documented double birth control measures for at least 3 months prior to randomization
• •Symptoms of PAD before the age of 40 years
• •Recent initiations or discontinuation of treatment by vasoactive agents (e.g., pentoxifylline, berprost sodium, papverine, isoxsuprine, nylidrin, cyclandelate, and niacin derivatives). Patients treated by cilostazol within 3 months prior to screening will also be excluded
• •Recent lower-extremity surgical or endovascular arterial reconstructions or sympathectomy, or recent deep venous thrombosis
• •Recent occurrence of at least one of the following: acute myocardial infarction, unstable angina, coronary artery bypass graft, percutaenous coronary intervention, transient ischemic attack or stroke
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.